Works matching IS 21534888 AND DT 2020 AND VI 11 AND IP 6
Results: 31
FoundationOne CDx Approved as Companion Diagnostic for Vitrakvi to Identify NTRK Fusions in Solid Tumors.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 42
- Publication type:
- Article
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 42
- By:
- Publication type:
- Article
FDA Expands FoundationOne Liquid CDx Indications for Several Mutations in Various Cancers.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 41
- Publication type:
- Article
FGFR Inhibition in Cholangiocarcinoma and Resistance to Therapy.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 41
- By:
- Publication type:
- Article
Cemiplimab Improves Survival versus Chemotherapy in Patients with Advanced NSCLC and PD-L1 ≥50%.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 40
- Publication type:
- Article
Novel Combinations Achieving Undetectable Minimal Residual Disease in Patients with CLL.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 1
- By:
- Publication type:
- Article
Industry Leaders Look Ahead to a New Administration.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 1
- Publication type:
- Article
First-Line Lorlatinib Shows "Astonishing Results" in Patients with ALK-Positive NSCLC.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 38
- By:
- Publication type:
- Article
Financial Toxicity Can Be Deadly for Patients with Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 36
- By:
- Publication type:
- Article
Multidisciplinary Cancer Care Starts and Ends with the Patient.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 34
- By:
- Publication type:
- Article
Innovations in Quality Care During the COVID-19 Pandemic: Lessons Learned.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 33
- By:
- Publication type:
- Article
Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 24
- Publication type:
- Article
Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 24
- Publication type:
- Article
Changes to the Oncology Care Model Spurred by the COVID-19 Pandemic.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 24
- By:
- Publication type:
- Article
Payers' Perspectives on Cancer Care.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 23
- Publication type:
- Article
Economics and Inequities in Cancer Care: AVBCC Keynote Address.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 23
- Publication type:
- Article
Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple-Negative Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 22
- Publication type:
- Article
Recruiting Minorities to Clinical Trials.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 22
- Publication type:
- Article
Expert Insights on Innovation in the Oncology Pipeline.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 21
- Publication type:
- Article
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 20
- Publication type:
- Article
Onureg First Drug Approved for Adults with AML in Remission.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 12
- Publication type:
- Article
New Research Highlights Barriers to Clinical Trial Participation.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 12
- By:
- Publication type:
- Article
Explosion of Treatment Regimens for Multiple Myeloma: Selecting the Right Option for the Right Patient.
- Published in:
- 2020
- By:
- Publication type:
- Proceeding
Aggressive Approach to High-Risk Smoldering Myeloma Gains Consensus.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 10
- By:
- Publication type:
- Article
Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 9
- Publication type:
- Article
CAR T-Cell Therapy May Not Be Needed in Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 9
- By:
- Publication type:
- Article
FDA Approves First Prostate-Specific Membrane Antigen- Targeted PET Imaging Drug for Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 8
- Publication type:
- Article
Xevinapant Improves Overall Survival in Patients with Head and Neck Squamous-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 7
- By:
- Publication type:
- Article
Dual RAF/MEK Inhibitor Shows Promising Activity in Tumors with RAS/RAF Mutations.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 6
- By:
- Publication type:
- Article
Sotorasib, First-in-Class KRAS G12C Inhibitor, Hailed as "Triumph of Drug Discovery".
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 1
- By:
- Publication type:
- Article
Social Determinants of Health in Cancer Care.
- Published in:
- Value-Based Cancer Care, 2020, v. 11, n. 6, p. 1
- By:
- Publication type:
- Article